ES2570994T3 - Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer - Google Patents

Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer

Info

Publication number
ES2570994T3
ES2570994T3 ES06844324T ES06844324T ES2570994T3 ES 2570994 T3 ES2570994 T3 ES 2570994T3 ES 06844324 T ES06844324 T ES 06844324T ES 06844324 T ES06844324 T ES 06844324T ES 2570994 T3 ES2570994 T3 ES 2570994T3
Authority
ES
Spain
Prior art keywords
4alkyl
5alkyl
substituted
3alkoxy
amidino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06844324T
Other languages
English (en)
Spanish (es)
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Choongwae Pharmaceutical Co Ltd
Original Assignee
Choongwae Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharmaceutical Co Ltd filed Critical Choongwae Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2570994T3 publication Critical patent/ES2570994T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06844324T 2005-11-08 2006-11-08 Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer Active ES2570994T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73465505P 2005-11-08 2005-11-08
PCT/US2006/043859 WO2007056593A2 (en) 2005-11-08 2006-11-08 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS

Publications (1)

Publication Number Publication Date
ES2570994T3 true ES2570994T3 (es) 2016-05-23

Family

ID=37890190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06844324T Active ES2570994T3 (es) 2005-11-08 2006-11-08 Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer

Country Status (8)

Country Link
US (2) US20070129353A1 (https=)
EP (1) EP1957516B1 (https=)
JP (1) JP5536336B2 (https=)
KR (1) KR101486490B1 (https=)
AU (1) AU2006311433B2 (https=)
CA (1) CA2629136C (https=)
ES (1) ES2570994T3 (https=)
WO (1) WO2007056593A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP2009538903A (ja) * 2006-05-30 2009-11-12 チュンウェ ファーマ コーポレーション 幹細胞分化の誘導または抑制のための組成物
WO2008030538A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
WO2009061349A1 (en) * 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
WO2009148192A1 (en) 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び/または癌前駆細胞の減少剤並びに癌の再発及び/または転移の予防剤
US20100022549A1 (en) * 2008-07-23 2010-01-28 The Scripps Research Institute Alpha-helix mimetic with functionalized pyridazine
AU2009286528B2 (en) * 2008-08-29 2014-07-17 Msd Italia S.R.L. Saturated bicyclic heterocyclic derivatives as Smo antagonists
WO2010030948A2 (en) * 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
CN102459271B (zh) * 2009-04-15 2014-07-02 Jw制药公司 回折模拟物的新化合物及其制备方法和用途
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CN102906566A (zh) 2010-02-03 2013-01-30 株式会社棱镜生物实验室 与天然变性蛋白质结合的化合物及其筛选方法
WO2011150360A1 (en) 2010-05-28 2011-12-01 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use
CN103209982B (zh) 2010-10-14 2016-03-16 Jw制药公司 反转模拟物的化合物、其制造方法及其用途
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US20140051706A1 (en) 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
CN103620024B (zh) 2011-06-09 2016-06-22 弗·哈夫曼-拉罗切有限公司 用于使多能干细胞分化为血管床细胞的方法
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2015056104A2 (en) 2013-10-18 2015-04-23 Hiroyuki Kouji Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
US11213527B2 (en) 2014-03-28 2022-01-04 National University Corporation Tottori University Inhibitory effect of low molecular weight compound on cancer and fibrosis
BR112017027227B1 (pt) * 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
EP3841197A1 (en) 2018-08-21 2021-06-30 F. Hoffmann-La Roche AG Methods for assessing transendothelial barrier integrity
WO2020079107A1 (en) 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag Synergistic transcription factors to induce high resistance transendothelial barrier
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CA3194606A1 (en) 2020-10-05 2022-04-14 Fuqiang Ruan Topical agents for dermatological applications
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2002303779A1 (en) * 2001-05-16 2002-11-25 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1444235B1 (en) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CA2502644A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
EP1599480B1 (de) * 2003-02-13 2010-06-30 Sanofi-Aventis Deutschland GmbH Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7390814B2 (en) * 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
EP1660502A2 (en) * 2003-08-28 2006-05-31 Choongwae Pharma Corporation MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION
US7915251B2 (en) * 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation

Also Published As

Publication number Publication date
EP1957516A2 (en) 2008-08-20
WO2007056593A2 (en) 2007-05-18
US8293743B2 (en) 2012-10-23
JP5536336B2 (ja) 2014-07-02
AU2006311433B2 (en) 2012-06-28
US20070129353A1 (en) 2007-06-07
US20100069333A1 (en) 2010-03-18
EP1957516B1 (en) 2016-03-09
AU2006311433A1 (en) 2007-05-18
CA2629136C (en) 2016-03-08
JP2009515890A (ja) 2009-04-16
WO2007056593A3 (en) 2007-07-12
KR101486490B1 (ko) 2015-01-27
CA2629136A1 (en) 2007-05-18
KR20080070060A (ko) 2008-07-29

Similar Documents

Publication Publication Date Title
ES2570994T3 (es) Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
DK1480644T3 (da) Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
EA201170176A1 (ru) Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента
HN2009001262A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5)
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
CY1106358T1 (el) Νεοι δικυκλικοι αναστολεις της ορμονοευαισθητης λιπασης
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
CO6541547A2 (es) Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DE602005023015D1 (de) Indolderivate als viruzide
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo